Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 6/20 | 0.61 |
| ▸ | DPP4 | P27487 | 2/20 | 0.50 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 4/20 | 0.46 |
| ▸ | MASP2 | O00187 | 6/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30918644 | 1.00 | HDAC2 (0.61) | HDAC2DPP4RPS6KB1F2MASP2 | |
| Hydrochloric Acid SCHEMBL30530772 | 0.98 | HDAC2 (0.60) | HDAC2DPP4RPS6KB1F2MASP2 | |
| Hydrochloric Acid SCHEMBL30471716 | 0.98 | HDAC2 (0.60) | HDAC2DPP4RPS6KB1F2MASP2 | |
| Trifluoroacetic Acid SCHEMBL23201154 | 0.91 | HDAC2 (0.53) | HDAC2DPP4RPS6KB1F2MASP2 | |
| Trifluoroacetic Acid SCHEMBL29880438 | 0.91 | HDAC2 (0.53) | HDAC2DPP4RPS6KB1F2MASP2 | |
| SCHEMBL197989 | 0.86 | HDAC2 (0.65) | HDAC2DPP4RPS6KB1F2AKR1C3 | |
| SCHEMBL197990 | 0.86 | HDAC2 (0.65) | HDAC2DPP4RPS6KB1F2AKR1C3 | |
| SCHEMBL199332 | 0.86 | HDAC2 (0.65) | HDAC2DPP4RPS6KB1F2AKR1C3 | |
| SCHEMBL8512122 | 0.86 | HDAC2 (0.65) | HDAC2DPP4RPS6KB1F2AKR1C3 | |
| SCHEMBL25396765 | 0.86 | HDAC2 (0.65) | HDAC2DPP4RPS6KB1F2AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230053342-A1 | IMIDAZOLIDINONE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2023-02-23 | — | — | US | claimed |
| EP-4056575-A1 | IMIDAZOLIDINONE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2022-09-14 | — | — | EP | claimed |
| CN-114599655-A | Imidazolidinone compound and preparation method and application thereof | 贝达药业股份有限公司 | 2022-06-07 | — | — | CN | claimed |
| CN-119350433-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-112867706-B | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118373875-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-07-23 | — | — | CN | disclosed |
| CN-118084935-A | Imidazolidinone compound as well as preparation method and application thereof | 贝达药业股份有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-117964684-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117964683-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-114599655-B | Imidazolidinone compound as well as preparation method and application thereof | 贝达药业股份有限公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-116685576-A | Cysteine protease inhibitors and methods of use thereof | 美商帕迪斯生物科学公司 | 2023-09-01 | — | — | CN | disclosed |
| WO-2023143401-A1 | COMPOUND SERVING AS MASP-2 INHIBITOR, PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR, AND USE THEREOF | 武汉朗来科技发展有限公司 | 2023-08-03 | — | — | WO | disclosed |
| US-20230053342-A1 | IMIDAZOLIDINONE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2023-02-23 | — | — | US | disclosed |
| EP-4056575-A1 | IMIDAZOLIDINONE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2022-09-14 | — | — | EP | disclosed |
| CN-114599655-A | Imidazolidinone compound and preparation method and application thereof | 贝达药业股份有限公司 | 2022-06-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230053342-A1 | IMIDAZOLIDINONE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, SLC5A11, CYP51A1 | HDAC2 2535/4885DPP4 1788/4885RPS6KB1 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.